📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

Guggenheim sets Pfizer stock with buy rating, $36 target

EditorAhmed Abdulazez Abdulkadir
Published 02/23/2024, 05:04 AM
© Reuters.
PFE
-

On Friday, Guggenheim initiated coverage on Pfizer Inc. (NYSE: NYSE:PFE) with a Buy rating, setting a price target of $36.00. The move comes after a period of significant underperformance for Pfizer shares, which have dropped more than 50% since mid-December 2021. This decline stands in contrast to the S&P 500's approximately 8% rise and the DRG index's roughly 25% increase in the same timeframe.

The analyst from Guggenheim noted that investor expectations for Pfizer's COVID-19 related assets, including the vaccine Comirnaty and the oral antiviral treatment Paxlovid, have now been adjusted to more realistic levels. Despite challenges facing several of Pfizer's major revenue streams, there is potential for near-term estimate increases. This optimism is based on the successful commercialization of upcoming opportunities, such as Padcev for first-line bladder cancer treatment and Abrysvo for RSV prophylactic vaccination.

Guggenheim's analysis also highlights that the low investor expectations currently set for Pfizer could lead to positive shifts in sentiment should the company achieve clinical success with its promising pipeline assets. These include treatments like vepdegestrant, VLA15, and ponsegromab. The firm suggests that these developments, coupled with Pfizer's current dividend yield of approximately 6%, provide a stable foundation for the stock as management continues to execute its strategic plans.

The analyst's comments underscore the potential for Pfizer to rebound from its recent underperformance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.